公开(公告)号：US20250084091A1

公开(公告)日：2025-03-13

申请号：US18558908

申请日：2022-05-04

Applicant: The Texas A&M University System

Inventor： James C. Sacchettini ,  Nian E. Zhou ,  Maloy Kumar Parai ,  Joonyoung Shin ,  Jeremy Lee Wood ,  Inna V. Krieger ,  Armando Flores ,  Arjun Acharya ,  Zhe Shi ,  Xuelin Bian ,  Su TANG ,  Radha Bam ,  Pradeep Kumar Jaiswal

IPC: C07D487/08 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/55 ,  A61K45/06 ,  C07D213/82 ,  C07D409/12 ,  C07D409/14 ,  C07D471/04 ,  C07D519/00

Abstract: Described herein are compounds and methods for the treatment of coronavirus infection. The compounds can function as an inhibitor of the main protease (Mpro) of coronaviruses. The compounds can include diphenylmethyl piperazine derivatives, diphenylmethyl piperidine derivatives, diphenylmethylidene piperidine derivatives, tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen derivatives, tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen derivatives, 6,11-dihydrobenzo[c][1]benzoxepin derivatives, 6,11-dihydrobenzo[c][1]benzothiepin derivatives, 5,5-dioxo-6,11-dihydrobenzo[c][1]benzothiepin derivatives, and 6-oxo-5,11-dihydrobenzo[c][1]benzazepin derivatives, as well as pharmaceutically acceptable salts, hydrates, and prodrugs thereof.

公开(公告)号：US10300071B2

公开(公告)日：2019-05-28

申请号：US15248844

申请日：2016-08-26

Applicant: The Texas A&M University System

Inventor： Manchi C M Reddy ,  James C. Sacchettini ,  Nian E. Zhou ,  Billy F. McCutchen

IPC: A61K31/428 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/423 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/501

Abstract: A composition comprising a drug selected from the group consisting of an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, a substituted quinol, or a salt, hydrate, or prodrugs thereof, or a combination thereof, in an amount and formulation sufficient to inhibit a mycobacterium is disclosed.

公开(公告)号：US10543200B2

公开(公告)日：2020-01-28

申请号：US15754244

申请日：2016-08-26

Applicant: The Texas A&M University System

Inventor： Manchi C M Reddy ,  James C. Sacchettini ,  Nian E. Zhou ,  Billy F. McCutchen

IPC: A61K31/44 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/541 ,  A61P33/02 ,  A61K31/423 ,  A61K31/496 ,  A61K31/498 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/7036

Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, one or more substituted quinols, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, or a combination thereof in an amount and formulation sufficient to sensitize the parasite to the drug, treating infection of a patient by a parasite with a drug, or to prevent symptomatic infection of a patient by a parasite with a drug.

公开(公告)号：US09677112B2

公开(公告)日：2017-06-13

申请号：US14401775

申请日：2013-05-15

Applicant: The Texas A&M University System ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： Jianghong Rao ,  Jeffrey D. Cirillo ,  Hexin Xie ,  James C. Sacchettini

IPC: C07D501/34 ,  C12Q1/34 ,  C07D501/24 ,  C07D501/26 ,  C07D501/30 ,  C07D501/57

CPC classification number: C12Q1/34 ,  C07D501/24 ,  C07D501/26 ,  C07D501/30 ,  C07D501/34 ,  C07D501/57 ,  G01N2333/986 ,  G01N2800/26

Abstract: β-Lactamase substrates and methods for using the substrates to detect β-lactamase diagnose tuberculosis.

公开(公告)号：US20150167048A1

公开(公告)日：2015-06-18

申请号：US14401775

申请日：2013-05-15

Applicant: The Texas A&M University System ,  The Board of Trustees of the Leland Stnaford Junior University

Inventor： Jianghong Rao ,  Jeffrey D. Cirillo ,  Hexin Xie ,  James C. Sacchettini

IPC: C12Q1/34 ,  C07D501/57

CPC classification number: C12Q1/34 ,  C07D501/24 ,  C07D501/26 ,  C07D501/30 ,  C07D501/34 ,  C07D501/57 ,  G01N2333/986 ,  G01N2800/26

Abstract: β-Lactamase substrates and methods for using the substrates to detect β-lactamase diagnose tuberculosis.

Abstract translation: β-内酰胺酶底物和使用底物检测β-内酰胺酶诊断结核病的方法。

公开(公告)号：US20210290571A1

公开(公告)日：2021-09-23

申请号：US17257770

申请日：2019-07-12

Applicant: The Texas A&M University System

Inventor： Shivatheja Soma ,  Vishal M. Gohil ,  James C. Sacchettini ,  Liam Guthrie

IPC: A61K31/165 ,  A61K33/34 ,  A61P3/02

Abstract: In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTRL ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.

公开(公告)号：US11083717B2

公开(公告)日：2021-08-10

申请号：US16720160

申请日：2019-12-19

Applicant: The Texas A&M University System

Inventor： Manchi C M Reddy ,  James C. Sacchettini ,  Nian E. Zhou ,  Billy F. McCutchen

IPC: A61K31/44 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/541 ,  A61P33/02 ,  A61K31/423 ,  A61K31/496 ,  A61K31/498 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/7036 ,  A61K31/427 ,  A61K31/5355 ,  A61K31/353 ,  A61K31/517

Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, one or more substituted quinols, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, or a combination thereof in an amount and formulation sufficient to sensitize the parasite to the drug, treating infection of a patient by a parasite with a drug, or to prevent symptomatic infection of a patient by a parasite with a drug.

公开(公告)号：US20190314381A1

公开(公告)日：2019-10-17

申请号：US16422594

申请日：2019-05-24

Applicant: THE TEXAS A&M UNIVERSITY SYSTEM

Inventor： Manchi CM Reddy ,  James C. Sacchettini ,  Nian E. Zhou ,  Billy F. McCutchen

IPC: A61K31/5377 ,  A61K31/501 ,  A61K31/496 ,  A61K31/454 ,  A61K31/423 ,  A61K31/498 ,  A61K31/44 ,  A61K31/428 ,  A61K31/4439

Abstract: A composition comprising a drug selected from the group consisting of an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, a substituted quinol, or a salt, hydrate, or prodrugs thereof, or a combination thereof, in an amount and formulation sufficient to inhibit a mycobacterium is disclosed.

公开(公告)号：US20240285555A1

公开(公告)日：2024-08-29

申请号：US18652683

申请日：2024-05-01

Applicant: The Texas A&M University System

Inventor： Shivatheja Soma ,  Vishal M. Gohil ,  James C. Sacchettini ,  Liam Guthrie

IPC: A61K31/165 ,  A61K33/34 ,  A61P3/02

CPC classification number: A61K31/165 ,  A61K33/34 ,  A61P3/02

Abstract: In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, APIS1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, APIS1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.

公开(公告)号：US20190142817A1

公开(公告)日：2019-05-16

申请号：US16249105

申请日：2019-01-16

Applicant: The Texas A&M University System

Inventor： James C. Sacchettini ,  Matthew W. Miller ,  Deeann Wallis ,  Nian E. Zhou ,  Theresa W. Fossum

IPC: A61K31/454 ,  A61K45/06 ,  A61K31/435 ,  A61K31/427 ,  A61K31/7048 ,  A61K47/54 ,  A61K31/5377

Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.